Cyclophosphamide Oral, Intravenous and Cardiac disease/cardiotoxicity
Result of checking the interaction of drug Cyclophosphamide Oral, Intravenous and disease Cardiac disease/cardiotoxicity for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy. Supraventricular arrhythmias and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide. The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents.
Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with preexisting cardiac disease. These patients should be closely monitored.
- "Product Information. Cytoxan (cyclophosphamide)." Bristol-Myers Squibb, Princeton, NJ.
Generic Name: cyclophosphamide
Brand Name: Cytoxan, Neosar, Cytoxan Lyophilized
Synonyms: Cyclophosphamide (oral and injection), Cyclophosphamide